Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
Identifieur interne : 003510 ( Ncbi/Merge ); précédent : 003509; suivant : 003511Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
Auteurs : Felicia Cosman ; Jane A. Cauley ; Richard Eastell ; Steven Boonen ; Lisa Palermo ; Ian R. Reid ; Steven R. Cummings ; Dennis M. BlackSource :
- The Journal of clinical endocrinology and metabolism [ 1945-7197 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents de maintien de la densité osseuse (administration et posologie), Agents de maintien de la densité osseuse (usage thérapeutique), Densité osseuse, Diphosphonates (administration et posologie), Diphosphonates (usage thérapeutique), Femelle, Fractures osseuses (), Fractures osseuses (épidémiologie), Humains, Imidazoles (administration et posologie), Imidazoles (usage thérapeutique), Ostéoporose (traitement médicamenteux), Post-ménopause, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Évaluation des risques.
- MESH :
- administration et posologie : Agents de maintien de la densité osseuse, Diphosphonates, Imidazoles.
- traitement médicamenteux : Ostéoporose.
- usage thérapeutique : Agents de maintien de la densité osseuse, Diphosphonates, Imidazoles.
- épidémiologie : Fractures osseuses.
- Adulte, Adulte d'âge moyen, Densité osseuse, Femelle, Fractures osseuses, Humains, Post-ménopause, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Évaluation des risques.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Bone Density, Bone Density Conservation Agents (administration & dosage), Bone Density Conservation Agents (therapeutic use), Diphosphonates (administration & dosage), Diphosphonates (therapeutic use), Female, Fractures, Bone (epidemiology), Fractures, Bone (prevention & control), Humans, Imidazoles (administration & dosage), Imidazoles (therapeutic use), Middle Aged, Osteoporosis (drug therapy), Postmenopause, Risk Assessment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Bone Density Conservation Agents, Diphosphonates, Imidazoles.
- chemical , therapeutic use : Bone Density Conservation Agents, Diphosphonates, Imidazoles.
- drug therapy : Osteoporosis.
- epidemiology : Fractures, Bone.
- prevention & control : Fractures, Bone.
- Adult, Aged, Aged, 80 and over, Bone Density, Female, Humans, Middle Aged, Postmenopause, Risk Assessment, Treatment Outcome.
Abstract
Data are needed to guide therapeutic decisions about stopping bisphosphonates after an initial treatment period.
DOI: 10.1210/jc.2014-1971
PubMed: 25215556
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F26
- to stream PubMed, to step Curation: 000F23
- to stream PubMed, to step Checkpoint: 000F23
Links to Exploration step
pubmed:25215556Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?</title><author><name sortKey="Cosman, Felicia" sort="Cosman, Felicia" uniqKey="Cosman F" first="Felicia" last="Cosman">Felicia Cosman</name><affiliation><nlm:affiliation>Helen Hayes Hospital (F.C.), West Haverstraw, New York 10993; Department of Medicine (F.C.), Columbia University College of Physicians and Surgeons, New York, New York 10032; Department of Epidemiology (J.A.C.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Academic Unit of Bone Metabolism (R.E.), University of Sheffield, Sheffield, United Kingdon, S5 7AU; Department of Experimental Medicine (S.B.); Leuven University Hospital, Leuven, B-3000 Belgium; Department of Epidemiology and Department of Biostatistics (L.P., S.R.C., D.M.B.), University of California San Francisco, San Francisco, California 94107; and Faculty of Medical and Health Sciences (I.R.R.), University of Auckland, Auckland, New Zealand, 1023.</nlm:affiliation><wicri:noCountry code="subField">1023</wicri:noCountry></affiliation></author><author><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A" last="Cauley">Jane A. Cauley</name></author><author><name sortKey="Eastell, Richard" sort="Eastell, Richard" uniqKey="Eastell R" first="Richard" last="Eastell">Richard Eastell</name></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name></author><author><name sortKey="Palermo, Lisa" sort="Palermo, Lisa" uniqKey="Palermo L" first="Lisa" last="Palermo">Lisa Palermo</name></author><author><name sortKey="Reid, Ian R" sort="Reid, Ian R" uniqKey="Reid I" first="Ian R" last="Reid">Ian R. Reid</name></author><author><name sortKey="Cummings, Steven R" sort="Cummings, Steven R" uniqKey="Cummings S" first="Steven R" last="Cummings">Steven R. Cummings</name></author><author><name sortKey="Black, Dennis M" sort="Black, Dennis M" uniqKey="Black D" first="Dennis M" last="Black">Dennis M. Black</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25215556</idno><idno type="pmid">25215556</idno><idno type="doi">10.1210/jc.2014-1971</idno><idno type="wicri:Area/PubMed/Corpus">000F26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F26</idno><idno type="wicri:Area/PubMed/Curation">000F23</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F23</idno><idno type="wicri:Area/PubMed/Checkpoint">000F23</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F23</idno><idno type="wicri:Area/Ncbi/Merge">003510</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?</title><author><name sortKey="Cosman, Felicia" sort="Cosman, Felicia" uniqKey="Cosman F" first="Felicia" last="Cosman">Felicia Cosman</name><affiliation><nlm:affiliation>Helen Hayes Hospital (F.C.), West Haverstraw, New York 10993; Department of Medicine (F.C.), Columbia University College of Physicians and Surgeons, New York, New York 10032; Department of Epidemiology (J.A.C.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Academic Unit of Bone Metabolism (R.E.), University of Sheffield, Sheffield, United Kingdon, S5 7AU; Department of Experimental Medicine (S.B.); Leuven University Hospital, Leuven, B-3000 Belgium; Department of Epidemiology and Department of Biostatistics (L.P., S.R.C., D.M.B.), University of California San Francisco, San Francisco, California 94107; and Faculty of Medical and Health Sciences (I.R.R.), University of Auckland, Auckland, New Zealand, 1023.</nlm:affiliation><wicri:noCountry code="subField">1023</wicri:noCountry></affiliation></author><author><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A" last="Cauley">Jane A. Cauley</name></author><author><name sortKey="Eastell, Richard" sort="Eastell, Richard" uniqKey="Eastell R" first="Richard" last="Eastell">Richard Eastell</name></author><author><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name></author><author><name sortKey="Palermo, Lisa" sort="Palermo, Lisa" uniqKey="Palermo L" first="Lisa" last="Palermo">Lisa Palermo</name></author><author><name sortKey="Reid, Ian R" sort="Reid, Ian R" uniqKey="Reid I" first="Ian R" last="Reid">Ian R. Reid</name></author><author><name sortKey="Cummings, Steven R" sort="Cummings, Steven R" uniqKey="Cummings S" first="Steven R" last="Cummings">Steven R. Cummings</name></author><author><name sortKey="Black, Dennis M" sort="Black, Dennis M" uniqKey="Black D" first="Dennis M" last="Black">Dennis M. Black</name></author></analytic><series><title level="j">The Journal of clinical endocrinology and metabolism</title><idno type="eISSN">1945-7197</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Bone Density</term><term>Bone Density Conservation Agents (administration & dosage)</term><term>Bone Density Conservation Agents (therapeutic use)</term><term>Diphosphonates (administration & dosage)</term><term>Diphosphonates (therapeutic use)</term><term>Female</term><term>Fractures, Bone (epidemiology)</term><term>Fractures, Bone (prevention & control)</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>Imidazoles (therapeutic use)</term><term>Middle Aged</term><term>Osteoporosis (drug therapy)</term><term>Postmenopause</term><term>Risk Assessment</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents de maintien de la densité osseuse (administration et posologie)</term><term>Agents de maintien de la densité osseuse (usage thérapeutique)</term><term>Densité osseuse</term><term>Diphosphonates (administration et posologie)</term><term>Diphosphonates (usage thérapeutique)</term><term>Femelle</term><term>Fractures osseuses ()</term><term>Fractures osseuses (épidémiologie)</term><term>Humains</term><term>Imidazoles (administration et posologie)</term><term>Imidazoles (usage thérapeutique)</term><term>Ostéoporose (traitement médicamenteux)</term><term>Post-ménopause</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bone Density Conservation Agents</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Osteoporosis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Fractures, Bone</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Fractures, Bone</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Ostéoporose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Fractures osseuses</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Bone Density</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Postmenopause</term><term>Risk Assessment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Densité osseuse</term><term>Femelle</term><term>Fractures osseuses</term><term>Humains</term><term>Post-ménopause</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Data are needed to guide therapeutic decisions about stopping bisphosphonates after an initial treatment period.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25215556</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>06</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation></Journal><ArticleTitle>Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?</ArticleTitle><Pagination><MedlinePgn>4546-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2014-1971</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Data are needed to guide therapeutic decisions about stopping bisphosphonates after an initial treatment period.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define significant predictors of fracture and quantify fracture incidence in risk factor-defined subgroups of women who discontinue zoledronic acid (ZOL) after 3 years of treatment. To determine if continuing ZOL reduces fracture risk in subgroups.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This study is based on data from the 3 year extension of HORIZON.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Subjects were in the ZOL arm of the Multicenter HORIZON trial.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">One thousand two hundred thirty three women who previously received 3 ZOL treatments during the Core trial.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Randomization to three additional annual ZOL (Z6, n = 616) or placebo infusions (Z3P3, n = 617).</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">The risk of morphometric vertebral fractures (MorphVertFx) and clinical nonvertebral fractures (NVF).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of MorphVertFx in Z3P3 was predicted by femoral neck (FN) t-score ≤-2.5 [OR 3.3 (1.4, 8.0), p = .008], total hip (TH) t-score ≤-2.5 [OR 4.0 (1.8, 9.0), p = .0007], and incident MorphVertFx during Core [OR 4.75 (1.4, 16.8), p < .015]. Incidence of NVF was predicted by TH t-score [for 1 decline, HR 1.7 (1.2, 2.6), p = .008], incident NVF during Core [HR 2.5 (1.2, 5.3), p = .014], and prevalent vertebral fracture [HR 3.0 (1.4, 6.3), p = .005]. For MorphVertFx, there were no significant treatment subgroup interactions; absolute fracture reductions with continued ZOL were greatest in high-risk subgroups. For NVF, there were no significant treatment reductions overall or in subgroups and no significant interactions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After 3 years of ZOL, in women who have a TH t-score above -2.5, no recent incident fracture and no more than one risk factor (almost 55% of the population), risk for subsequent fracture (over three additional years) is low if treatment is discontinued (for MorphVertFx, average risk 3.2% and for NVF, average risk 5.8%). In these patients, discontinuation for up to 3 years is reasonable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cosman</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Helen Hayes Hospital (F.C.), West Haverstraw, New York 10993; Department of Medicine (F.C.), Columbia University College of Physicians and Surgeons, New York, New York 10032; Department of Epidemiology (J.A.C.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261; Academic Unit of Bone Metabolism (R.E.), University of Sheffield, Sheffield, United Kingdon, S5 7AU; Department of Experimental Medicine (S.B.); Leuven University Hospital, Leuven, B-3000 Belgium; Department of Epidemiology and Department of Biostatistics (L.P., S.R.C., D.M.B.), University of California San Francisco, San Francisco, California 94107; and Faculty of Medical and Health Sciences (I.R.R.), University of Auckland, Auckland, New Zealand, 1023.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauley</LastName><ForeName>Jane A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Eastell</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Boonen</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Palermo</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Dennis M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K006312/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>6XC1PAD3KF</RegistryNumber><NameOfSubstance UI="C088658">zoledronic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Clin Biochem. 2015 Jan;52(1):183</RefSource><PMID Version="1">28071075</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Clin Biochem. 2015 Jan;52(1):183</RefSource><PMID Version="1">28071076</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050723" MajorTopicYN="N">Fractures, Bone</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25215556</ArticleId><ArticleId IdType="doi">10.1210/jc.2014-1971</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Black, Dennis M" sort="Black, Dennis M" uniqKey="Black D" first="Dennis M" last="Black">Dennis M. Black</name><name sortKey="Boonen, Steven" sort="Boonen, Steven" uniqKey="Boonen S" first="Steven" last="Boonen">Steven Boonen</name><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A" last="Cauley">Jane A. Cauley</name><name sortKey="Cosman, Felicia" sort="Cosman, Felicia" uniqKey="Cosman F" first="Felicia" last="Cosman">Felicia Cosman</name><name sortKey="Cummings, Steven R" sort="Cummings, Steven R" uniqKey="Cummings S" first="Steven R" last="Cummings">Steven R. Cummings</name><name sortKey="Eastell, Richard" sort="Eastell, Richard" uniqKey="Eastell R" first="Richard" last="Eastell">Richard Eastell</name><name sortKey="Palermo, Lisa" sort="Palermo, Lisa" uniqKey="Palermo L" first="Lisa" last="Palermo">Lisa Palermo</name><name sortKey="Reid, Ian R" sort="Reid, Ian R" uniqKey="Reid I" first="Ian R" last="Reid">Ian R. Reid</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003510 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003510 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25215556
|texte= Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25215556" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |